Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ (NGS) NASDAQ (NGS) Primary 
XMEX 
Recursion Pharmaceuticals, Inc. (RXRX) Q4 2025 Earnings Call Transcript
Recursion Pharmaceuticals, Inc. (RXRX) Q4 2025 Earnings Call Transcript
RXRX Q4 Loss Narrower Than Expected, Revenues Increase Y/Y, Stock Up
Recursion Pharmaceuticals stock up on narrower Q4 loss as revenues jump on Roche milestone, beating estimates and boosting cash runway into 2028.
Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider
In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $3.53, indicating a +2.02% shift from the previous trading day.
Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to Know
Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.85, moving 3.27% from the previous trading session.
Recursion Pharmaceuticals (RXRX) Suffers a Larger Drop Than the General Market: Key Insights
In the closing of the recent trading day, Recursion Pharmaceuticals (RXRX) stood at $3.9, denoting a -4.88% move from the preceding trading day.
Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors
Recursion Pharmaceuticals (RXRX) reached $4.32 at the closing of the latest trading day, reflecting a -3.36% change compared to its last close.
Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors
The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $4.73, representing a -4.64% change from its previous close.
Recursion Pharmaceuticals, Inc. (RXRX) Presents at 28th Annual Needham Growth Conference Transcript
Recursion Pharmaceuticals, Inc. (RXRX) Presents at 28th Annual Needham Growth Conference Transcript
Recursion Pharmaceuticals (RXRX) Stock Drops Despite Market Gains: Important Facts to Note
Recursion Pharmaceuticals (RXRX) closed at $4.65 in the latest trading session, marking a -4.12% move from the prior day.
Recursion Pharmaceuticals, Inc. (RXRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Recursion Pharmaceuticals, Inc. (RXRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
What's Happening With RXRX Stock?
Recursion Pharmaceuticals (NASDAQ: RXRX) experienced an 11% increase in stock price on Wednesday after JP Morgan raised its rating, noting the promising potential of its MEK inhibitor program. However, here's a reality check: RXRX remains down by 35% year-to-date and is trading below $5.
Recursion Pharmaceuticals (RXRX) Up 6.5% Since Last Earnings Report: Can It Continue?
Recursion Pharmaceuticals (RXRX) reported earnings 30 days ago. What's next for the stock?
